OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

NCT05949424 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Ovarian Carcinoma
Thyroid Carcinoma
Breast Carcinoma
Endometrium Carcinoma

Interventions

DRUG: Olaparib
DRUG: Lenvatinib
DRUG: Sunitinib
DRUG: Palbociclib
DRUG: Pazopanib
DRUG: Olaparib
DRUG: Lenvatinib
DRUG: Sunitinib
DRUG: Palbociclib
DRUG: Pazopanib

Sponsor

University Medical Center Groningen